文献速递病毒性肝炎艾滋病与性传播感染

德国阿片类替代治疗患者丙肝患病率与发病率:前瞻性队列研究

Hepatitis C Virus Prevalence and Incidence in a Large Nationwide Sample of Patients in Opioid Substitution Treatment in Germany: A Prospective Cohort Study.
PubMed 文献 · Clin Infect Dis · 2020-01-01

结论认为德国OST是治疗慢性HCV感染和预防新发感染的有效场景。

要点

  • OST患者HCV抗体阳性率58.8%,RNA阳性率27.3%。
  • HCV年发病率为2.5例/100人年。
  • 女性、就业、年轻、OST及阿片依赖时间短与较低RNA阳性率相关。

核心结论

  • 德国OST患者中HCV RNA阳性率和HCV发病率均较低,提示OST是治疗慢性HCV感染和预防新发感染的有效场景。

研究设计与样本

  • 前瞻性队列研究,2014年10月至2016年6月从德国随机选取OST机构收集常规诊疗基线数据,基线HCV抗体阴性者12个月后随访计算发病率。

主要发现

  • HCV抗体阳性率为58.8%(95%CI 56.8%-60.8%),HCV RNA阳性率为27.3%(95%CI 25.5%-29.2%)。
  • 基线时528例(21.4%)既往接受过抗病毒治疗。
  • HCV RNA阳性率较低与女性、就业、较年轻、较短OST时间及较短阿片依赖时间相关。
  • HCV发病率为2.5例/100人年。

临床怎么用

  • 在OST患者中扩大HCV检测和治疗覆盖,可作为减少该高危人群HCV感染的公共卫生策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatitis C virus (HCV) infection is highly prevalent among people who inject drugs (PWID). Accurate data on HCV prevalence and incidence rates among patients receiving opioid substitution treatment (OST) are needed to estimate the current and future burden of HCV infections in this high-risk population. METHODS: Baseline data from routine care were collected between October 2014 and June 2016 from randomly selected OST facilities in Germany. The primary outcome measure was the HCV status (antibody and RNA prevalence). Patients who were HCV antibody-negative at baseline were followed up after 12 months to calculate the HCV incidence rate. RESULTS: Sixty-three facilities from 14 German Federal States provided clinical data for a total of 2466 OST patients. HCV antibody and HCV RNA prevalence were 58.8% (95% confidence interval [CI], 56.8%-60.8%) and 27.3% (95% CI, 25.5%-29.2%), respectively. At baseline, a total of 528 patients (21.4%) had previously undergone antiviral treatment. Moreover, lower HCV RNA prevalence was associated with female gender, employment, younger age, and shorter duration of OST and opioid dependence. The HCV incidence rate was 2.5 cases per 100 person-years. CONCLUSIONS: The low HCV RNA prevalence and HCV incidence rates confirm that OST in Germany is an effective setting both for treating chronic HCV infections and for preventing new infections among PWID. Scaling up the provision of OST, HCV testing, and HCV treatment among OST patients are important public health strategies for reducing HCV infections in this high-risk population.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Schulte B, Schmidt CS, Strada L, et al. Hepatitis C Virus Prevalence and Incidence in a Large Nationwide Sample of Patients in Opioid Substitution Treatment in Germany: A Prospective Cohort Study. Clin Infect Dis. 2020. PMID: 31631215. doi:10.1093/cid/ciz661

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。